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Abstract: 
Background: For the last 17 years, the UK has employed a routine influenza vaccination programme 
with the aim of reducing the spread of seasonal influenza. In mid-2000, the programme moved from 
a purely risk-based approach to a risk and age group targeted approach with all those aged 65+ years 
being included. To date, there has been no assessment of the population effectiveness of this age 
targeted policy in Scotland.  
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Objectives: Statistical modelling techniques were used to determine what impact the routine 
vaccination of those aged 65+ years has had on influenza related morbidity and mortality in 
Scotland. 
Methods: Two Poisson regression models were developed using weekly counts of all-cause 
mortality, cause specific mortality and emergency hospitalisations for the period 1981  2012, one 
using week-in-year and the other using temperature to capture the seasonal variability in 
mortality/hospitalisations. These models were used to determine the number of excess 
deaths/hospitalisations associated with the introduction of the local risk and age-based vaccination 
programme in 2000. 
Results: Routinely vaccinating those aged 65+ years is associated with a reduction in excess all-
cause mortality, cardiovascular and COPD related mortality and COPD related hospitalisations. 
Our analysis suggests that using the week-in-year model, on average, 732 (95%CI 66  1,398) 
deaths from all-causes, 248 (95%CI 10  486) cardiovascular related deaths, 123 (95%CI 28  218) 
COPD related deaths, and 425 (95%CI 258  592) COPD related hospitalisations have been 
prevented each flu season among the those aged 65+. Similar results were found using the 
temperature model. There was no evidence to suggest that the change in policy was associated with 
reductions in influenza/pneumonia related mortality or influenza/cardiovascular related 
hospitalisations.  
Conclusions: Routinely vaccinating those aged 65+ years appears to have reduced influenza related 
morbidity and mortality in Scotland. With the childhood vaccination programme well underway, 
these data provide an importance benchmark which can be used to accurately assess the impact of 
this new seasonal influenza vaccination programme. 
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1. Introduction 
Every winter the UK experiences a seasonal influenza epidemic that affects the morbidity and 
mortality of thousands of its citizens and puts increased pressure on NHS resources 
(1, 2)
. For healthy 
individuals, influenza is a self-limiting, though debilitating, illness from which full recovery is usually 
attained within 2  7 days 
(2, 3)
. There are some subsets of the population, however, who have been 
shown to have a higher risk of influenza associated morbidity and mortality 
(4-9)
. Although the extent 
to which influenza increases morbidity and mortality varies from year to year, the virus continues to 
impose a considerable economic burden on society 
(10, 11)
. As a result, seasonal influenza epidemics 
are considered to be a significant annual public health threat. 
Since the late 1960s, the UK has sought to limit the healthcare burden associated with influenza 
via a national vaccination programme. The programme initially targeted individuals who were at 
highest risk of influenza related morbidity and mortality and was continually expanded to 
incorporate a wider range of risk groups 
(2-4)
. In 2000, the programme was extended to include all 
persons aged 65+ years, moving the UK's vaccination policy from a risk based to a risk and age-based 
strategy. More recently, in 2012, the Joint Committee on Vaccination and Immunisation (JCVI) 
recommended the inclusion of those aged 2  17 years in the routine vaccination programme by 
offering intranasally administered Live cold-Adapted Influenza Vaccine (LAIV)  Fluenz 
(12)
. Each of 
the constituent countries within the United Kingdom endorsed this JCVI recommendation which has 
since become government policy. The phased introduction of this new extension began in 2013 with 
the routine immunisation of children aged 2  3 years with extensions to incorporate older age 
groups in subsequent years 
(13, 14)
. Although healthy children are less likely to experience severe 
influenza related morbidity and mortality 
(15)
, they are 2  3 times more likely to be ill with influenza 
(14)
 and are a well-documented transmitter of the virus 
(16, 17)
. Previous transmission modelling and 
cost-effectiveness studies suggest  the JCVI's recommendations will increase the overall efficiency of 
the influenza vaccination programme 
(18)
 and offer a highly cost-effective way of providing this risk 
group with direct protection against the impact of flu 
(19)
. The reduction in flu circulation resulting 
from the vaccination of children should offer indirect protection to older adults and those with 
clinical risk factors, therefore reducing the number of severe flu cases and flu related deaths in this 
subset of the population 
(20-23)
.  
A clear understanding of how changes to the UKs vaccination programme has affected influenza 
related morbidity and mortality is key to providing a benchmark from which policy makers can 
assess the success of the vaccination programme. While there is evidence to suggest that the 
influenza vaccine is effective at preventing influenza illness and its complications 
(24-30)
, the 
population effectiveness of the UK vaccination programme is not fully understood. While previous 
modelling work in England suggests that the vaccination programme, which targets clinical risk 
groups as well as individuals aged 65+ years, is cost-effective 
(24)
, and associated with a reduction in 
the incidence of laboratory confirmed influenza illness 
(24)
 as well as reduced levels of pneumonia 
and influenza related mortality 
(31)
, the same knowledge does not exist for Scotland. Understanding 
how many deaths/hospitalisations have been prevented among the over 65s is an important first 
step in this direction. Such work would (a) provide an estimate of the population effectiveness of 
the vaccination programme following the mid-2000 extension, and (b) allow a comparison to 
similar analyses using more recent data so that health care professionals can assess the changes in 
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vaccination effectiveness following the 2013/14 pilot and subsequent extension to all 2  11-year 
olds.  
The aim of this analysis is to use routine influenza surveillance data collected in Scotland to 
develop models that can be used to evaluate the population effectiveness of the national seasonal 
influenza vaccination programme. In particular, we are going to estimate the number of excess 
deaths/hospitalisations that may be been prevented by the mid-2000 policy recommendation to 
routinely vaccinate all persons aged 65+ years.  
 
2. Methods 
2.1. Data Sources 
We use yearly mid-year estimates of population size along with data on mortality and 
emergency hospitalisations for this analysis. Weekly counts of all-cause mortality, cause specific 
mortality and emergency hospitalisations in Scotland from 1981  2012 were provided by Health 
Protection Scotland. These data were extracted from the ACaDMe (Acute, Cancer, Deaths and 
Mental Health) datamart at Public Health Intelligence (PHI) which contains linked inpatient and 
daycase (SMR01), mental health (SMR04), cancer registration (SMR06) and death (GRO) records 
from 1981 to the present day 
(32)
. The cause specific mortality data lists the number of influenza, 
pneumonia, cardiovascular (diseases of the circulatory system); COPD (chronic lower respiratory 
disease, lung diseases due to external agents and other respiratory diseases) and trauma (hernia, 
injury, poisoning, diseases of the appendix and other external causes) related deaths recorded each 
week for the period of interest. The emergency hospitalisation data records the number of 
emergency hospital admissions for each patient in Scotland and uses the same disease categories as 
the cause specific mortality data. Mid-year estimates of population size for the period of interest 
were obtained from the National Records of Scotland 
(33)
. All of these data were broken down by 
gender (male or female) and age category (0  1, 2  4, 5  12, 13  17, 18  44, 45  64, 65  74, 75  
84, and 85+ years). 
Weekly spatial temperature data for the geographical centre of Scotland are used to account for 
the direct effect on temperature on the seasonal variation in mortality and hospitalisations. We use 
data obtained from the British Atmospheric Data Centre 
(34)
 along with Shepard's inverse distance 
weighting methods 
(35)
 to estimate weekly minimum and average air temperatures for the period of 
interest. 
 
2.2. Modelling the number of deaths/hospitalisations for a given week in the year 
We use Generalised Additive Models (GAMs) to derive Poisson regression models to estimate 
the expected number of deaths/hospitalisations for a given week in the year 
(36, 37)
. 
We use two different GAMs in this analysis. The first GAM assumes that the seasonal variability 
in mortality/hospitalisations is described solely by the time of year by defining  a variable that 
represents the location of the mid-point of a given week as a proportion of the number of Weeks 
In that Year. We denote this model the Week In Year (WIY) model. The second GAM assumes that 
the seasonal variability in mortality/hospitalisations is described solely by changes in 
temperature. We denote this model the Seasonal Temperature (ST) model. Both models contain an 
offset term to allow for changes in the population size/number of hospitalisations over time. When 
analysing mortality, the offset is equal to the logarithm of the population at risk. This offset is not 
suitable for the analysis of hospitalisations since the number of hospitalisations per head of 
population (population at risk offset) changes more rapidly than the number of hospitalisations per 
head of hospitalised population (offset equal to the logarithm of the total number of hospital 
admissions). Therefore, when analysing hospitalisations, the offset is equal to the logarithm of the 
total number of emergency hospitalisations. 
Both models are fitted to a dataset which contains all data from 1981  mid-2000 and summer 
data from mid-2000  2012. Here summer refers to be the fixed period covering weeks 10  45 of 
any given year, roughly March to October, thus ensuring that there were a sufficient number of 
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weeks for the winter season for the model. A stepwise regression method is used to derive the best 
fitting models. Predictor variables (age category, gender, year, week-in-year, flu season, minimum 
temperature and temperature severity) are either added to or removed from the regression 
equation depending on which step would provide a significant increase in the model fit (measured 
by the Generalised Cross Validation (GCV) score). Here, week-in-year is a continuous variable that 
denotes the location of the mid-point of a given week as a proportion of the number of weeks in 
that year, and minimum temperature is a continuous variable that denotes the weekly minimum air 
temperature for the geographical centre of Scotland. Temperature severity is a categorical variable 
with five levels (0 to 4) as shown in Table 1 that records how mild or severe the weather was 
during a particular flu season. The cut-off values of -0.6
o
, -1.27
o
 and -2.5
o
 correspond to the 1st, 2nd 
and 3rd quartiles of the dataset that contained the negative weekly minimum air temperatures. 
 
Severity Value 
Minimum air 
temperature (x) 
0 x д 0o
1 -0.6
o г x < 0o
2 -1.27
o г x < -0.6o
3 -2.5
o г x < -1.27o
4 X < -2.5
o
 
Table 1: Cut-off values used to define the temperature severity variables. The cut-off values of -0.6
o
, -1.27
o
 and -2.5
o
 
correspond to the 1
st
, 2
nd
 and 3
rd
 quartiles of the dataset that contained the negative weekly minimum air temperatures. 
We find that the best fitting WIY GAM is a function of year, week-in-year, age category and 
gender that models the number of deaths/hospitalisations in a given week t, for age group a and 
sex s (࡯࢕࢛࢔࢚࢚ࢇ࢙ሻ using the following equation: ܔܗ܏ሺ࡯࢕࢛࢔࢚࢚ࢇ࢙ሻ ൌܗ܎܎ܛ܍ܜ൅ࢼ૙ ൅ ࢌ૚ሺ࢟ࢋࢇ࢘ሻ ൅ ࢼ૛ࢍࢋ࢔ࢊࢋ࢘ ൅ ࢼ૜ࢇࢍࢋ ൅ ࢌ૛ሺ࢝ࢋࢋ࢑ െ ࢏࢔ െ ࢟ࢋࢇ࢘ሻ 
where ࢌ࢏ denotes a cubic regression spline. Similarly, we find that the best fitting ST GAM is a 
function of year, minimum temperature, gender, age category and temperature severity that 
models the number of deaths/hospitalisations using the following equation: ܔܗ܏ሺ࡯࢕࢛࢔࢚࢚ࢇ࢙ሻ ൌܗ܎܎ܛ܍ܜ൅ࢼ૙ ൅ ࢌ૚ሺ࢟ࢋࢇ࢘ሻ ൅ ࢼ૛ࢍࢋ࢔ࢊࢋ࢘ ൅ ࢼ૜ࢇࢍࢋ ൅ ࢌ૛ሺ࢓࢏࢔࢚ࢋ࢓࢖ሻ ൅࢙ࢋ࢜ࢋ࢘࢏࢚࢟.  
Both GAMs model the general trend of decreasing mortality over time using separate cubic 
regression splines for each gender, with 10  15 knot points (equivalent to one every 2  3 years), 
and the seasonal variability in mortality/hospitalisations using a cyclic cubic regression spline with 20 
knot points (equivalent to one every 2.5 weeks). The WIY (ST) model uses week in year (minimum 
temperature) to capture the seasonal variability in mortality. We follow the general purpose 
approach described in the documentation for the R package mgcv 
(38)
 to identify the correct number 
of knots for each spline. 
The best fitting GAMs are used to predict the weekly number of deaths/hospitalisations for the 
period 1981  2012. These predictions correspond to the number of deaths/hospitalisations that 
would be expected under the pre-mid-2000 (risk based) vaccination policy. For each outcome of 
interest, we calculate the number of excess observations (defined as observed count minus 
expected count) for each flu season (week 46  week 9). To quantify the change in policy's impact on 
excess deaths/hospitalisations, we follow the work of Mann et al. 
(31)
 and fit a Gaussian regression 
model to these data. For the ST model, we use a model that contains a dummy variable that takes 
the value 0 for 1981  mid-2000 and 1 for mid-2000  2012 to capture the mid-2000 change in 
vaccination policy. For the WIY model, we use the same dummy variable as the ST model as well as a 
second variable that accounts for the minimum air temperature observed in each flu season. 
All the analysis is carried out using R version 3.10 
(39)
 and over-dispersion is tested for using the 
over-dispersion test provided by the qcc R package 
(40)
. A 5% significance level is used throughout 
and 95% confidence intervals are based upon a normal distribution. 
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2.3. Sensitivity analysis 
We conduct a sensitivity analysis using the ST model for those aged 65+ years to investigate how 
our model fits and estimates for the number deaths/hospitalisations prevented are affected when 
we (a) use minimum instead of average air temperature to define seasonality, and (b) allow the flu 
season to vary from year to year corresponding to the national influenza surveillance data on 
consultation rates (reports per 100,000 population) from Health Protection Scotland. Each flu season 
starts when the consultation rate exceeds 50 and ends when it falls below 50. 
 
3. Results 
3.1. All-cause mortality  
Weekly all-cause mortality for those aged 65+ years in Scotland for the period 1981  2012 
ranged from 692 deaths (2010 week 29) to a maximum of 1,930 deaths (1989 week 50). The 
maximum number of deaths recorded under the risk-based vaccination policy (pre-mid-2000) was 
1,930 while the maximum number of deaths under the risk and age-based vaccination policy (post 
mid-2000) was 1,192 (2007 week 2). Females aged 75  84 (85+) years were the greatest 
contributors to the pre- (post-) policy change maxima (n = 457, 288, respectively). 
 
 
 
Figure 1. Observed weekly all-cause mortality for those aged 65 and over (circles) with (a) WIY model predictions (solid 
black line), and (b) ST model predictions (solid black line). The dotted vertical line indicates the change in policy from a risk 
based vaccination strategy to a risk and age-based vaccination strategy.  
From Figure 1 we can see that although both models are able to capture the long-term 
trends and the seasonal variation in the data, there are a number of instances where the models are 
not able to predict the number of deaths observed in moderate/severe influenza epidemics (1989  
1990 and 1999  2000, for example). Excess all-cause mortality for each flu season is shown in Figure 
2 where it is evident that, prior to the policy change in 2000, there are instances where the model 
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over-predicts (negative excess all-cause mortality) and under-predicts (positive excess all-cause 
mortality). This is a consequence of using both winter and summer data to fit the models prior to 
2000. After the policy change, however, there are few instances of under-prediction and many more 
instances of over-prediction, suggesting that excess mortality has decreased in the period following 
the change in vaccination policy. It is worth noting that the model fits for the ST model were 
slightly better than those for the WIY model. 
There is evidence to suggest that there has been a significant reduction in excess all-cause 
mortality among those aged 65+ years following the mid-2000 change in vaccination policy (WIY: p 
= 0.019, ST: p = 0.025) with both models predicting similar estimates of deaths prevented each flu 
season (WIY: 732 (95%CI 66  1,398); ST: 775 (95%CI 131  1,418)) as shown in Table 2. Analysis of 
the three age groups that make up the 65+ category (65  74, 75  84, and 85+) suggests that 
significant reductions in all-cause mortality have been observed in each of these age groups (WIY: p 
= 0.018; 0.034; 0.004; ST: p = 0.005; 0.020; 0.020, respectively). The greatest reductions have been 
among those aged 85 and over while the smallest reductions have been among those aged 65  74 
(Table 2). 
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Figure 2. Excess all-cause mortality (defined as ob
Estimates obtained with (a) WIY model prediction
that is available from 2001. 
 
served minus predicted) for those aged 65 and over by flu season
s, and (b) ST model predictions.  Figure (c) shows the vaccine upta
 
. 
ke data 
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Age Group 
Reduction
a
(WIY model) Reduction
a
(ST model) 
Mean 95%CI
**
Mean 95%CI
**
 
65+ 732 66  1,398 775 131  1,418 
65  74 179 29  330 216 75  358  
75  84 293 21  565 327 67  588  
85+ 384 130  637 330 69  594 
**
CI, Confidence Interval, based on a normal distribution.
a
The number of deaths in the individual age categories may not sum to the total due 
to rounding errors. 
 
Table 2. Estimates for the reduction in all-cause mortality among those aged 65+ years following the mid-2000 change in 
policy from a risk-based vaccination strategy to a risk and age-based vaccination strategy. 
 
3.2. Cause specific mortality 
Among those aged 65+ years, mortality attributable to influenza, pneumonia, cardiovascular 
disease, COPD and trauma were highly variable. Influenza related mortality ranged from 0 to 139 
deaths (1989 week 50) while pneumonia, cardiovascular, COPD and trauma related mortality ranged 
from 17 (2012 week 29) to 297 (1989 week 50), 183 (1989 week 34) to 771 (1989 week 51), 16 (1983 
week 34) to 180 (2000 week 1), and 0 to 65 (2000 week 1) deaths, respectively. Recorded instances 
of influenza related mortality were relatively rare: only 321 (30.7%) of the 1,044 time points pre-
policy change and 55 (8.8%) of the 626 time points post-policy change contained non-zero entries. 
 
Age Group 
Reduction
*a
(WIY model) Reduction
*a
(ST Model) 
Mean 95%CI
**
Mean 95%CI 
**
 
Influenza related mortality
65+ 10 -50  70 15 -37  66 
65  74 0 -9  9 1 -8  10 
75  84 3 -21  27 6 -15  27 
85+ 6 -20  32 8 -16  31 
 
Pneumonia related mortality
65+ 62 -104  229 85 -60  236 
65  74 8 -17  33 13 -9  35 
75  84 12 -52  77 26 -32  84 
85+ 51 -30  132 54 -20  127 
 
Cardiovascular related mortality
65+ 248 10  486 310 105  515 
65  74 58 18  91 82 25  139 
75  84 108 5  212 138 53  223 
85+ 110 22  197 116 32  200 
 
COPD related mortality 
65+ 167 75  259 123 28  218 
65  74 55 18  91 45 10  81 
75  84 64 21  107 49 2  95 
85+ 40 21  59 25 3  48 
Trauma related mortality
65+ -6 -28  15 -4 -28  19 
65  74 -6 -14  2 -5 -13  3 
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75  84 -8 -18  2 -7 -17  3 
85+ -11 -24  1 10 -5  25 
*
The number of influenza, pneumonia, cardiovascular, COPD and trauma related 
deaths prevented each flu season. 
**
CI, Confidence Interval, based on a normal distribution.
a
The number of deaths in the individual age categories may not sum to the total 
due to rounding errors. 
 
Table 3. Estimates for the reduction in influenza, pneumonia, cardiovascular, COPD and trauma related deaths following 
the mid-2000 change in policy from a risk-based vaccination strategy to a risk and age-based vaccination strategy. 
Confidence intervals that contain zero indicate mortality categories that were not affected by the change in vaccination 
policy. 
 
The model predictions for the 65+ grouping are presented in Table 3. As expected, there is no 
evidence of a reduction in trauma related mortality following the change in vaccination policy. 
Furthermore, there is no evidence of a reduction in influenza and pneumonia related mortality. Our 
analysis does, however, find evidence to suggest that there has been a significant reduction in 
cardiovascular (WIY: 248 (95%CI 10  486); ST: 310 (95%CI 105  515)) and COPD (WIY: 167 (95%CI 
75  259); ST: 123 (95%CI 28  218)) related mortality (Table 3). 
 
3.3. Cause specific emergency hospitalisations 
Influenza, pneumonia, cardiovascular disease, COPD and trauma related hospitalisations 
amongst those aged 65+ years were highly variable. Emergency hospitalisations attributable to 
influenza ranged from 0 to 88 (2000 week 1) while those attributable to pneumonia, cardiovascular, 
COPD and trauma ranged from 24 (1982 week 32) to 407 (1999 week 52), 353 (1982 week 29) to 934 
(1995 week 52), 45 (1983 week 43) to 666 (1999 week 52), and 188 (1981 week 39) to 740 (2008 
week 49), respectively. 
 
Age Group 
Reduction
*a
(WIY model) Reduction
*a
(ST Model) 
Mean 95%CI
**
Mean 95%CI 
**
 
Influenza related hospitalisations
65+ 21 -22  65 24 -14  62 
65  74 5 -10  20 7 -8  21 
75  84 10 -10  29 10 -7  26 
85+ 6 -5  16 6 -2  14 
 
Pneumonia related hospitalisations
65+ 245 104  385 147 -4  298 
65  74 64 19  109 44 -2  91 
75  84 136 70  202 75 5  145 
85+ 41 4  78 14 -27  55 
 
Cardiovascular related hospitalisations
65+ 42 -118  202 52 -107  211 
65  74 10 -64  84 15 -57  87 
75  84 25 -48  98 14 -57  86 
85+ 13 -29  56 43 0  85 
 
COPD related hospitalisations
65+ 425 258  592 236 40  431 
65  74 201 111  290 115 9  221 
75  84 167 99  234 94 21  167 
85+ 53 28  78 25 0  85 
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Trauma related hospitalisations
65+ 83 -51  216 -41 -153  72 
65  74 26 -38  90 -34 -88  21 
75  84 6 -54  66 -41 -94  13 
85+ -11 -3  69 27 -9  63 
*
The number of influenza, pneumonia, cardiovascular, COPD and trauma related 
hospitalisations prevented each flu season. 
**
CI, Confidence Interval, based on a normal distribution.
a
The number of hospitalisations in the individual age categories may not sum to the 
total due to rounding errors. 
 
Table 4. Estimates for the reduction in influenza, pneumonia, cardiovascular, COPD and trauma emergency hospitalisations 
following the mid-2000 change in policy from a risk-based vaccination strategy to a risk and age-based vaccination strategy. 
Confidence intervals that contain zero indicate hospitalisation categories that were not affected by the change in 
vaccination policy. 
 
Estimates for the number of hospitalisations prevented among the 65+ grouping are presented 
in Table 4. Our analysis shows that there is no evidence to suggest that the change in policy has had 
an effect on trauma, influenza and cardiovascular related hospitalisations. There is, however, 
evidence to suggest that there has been a significant reduction in COPD related hospitalisations 
amongst those aged 65+ years (WIY: 425 (95%CI 258  592); ST: 236 (95%CI 40  431)). The greatest 
reductions in COPD hospitalisations have been among those aged 65 74 while the smallest 
reductions have been among those aged 85+ years. Furthermore, the two models produce slightly 
contradictory results when we analyse pneumonia related hospitalisations: the WIY model finds 
evidence of a significant reduction in these hospitalisations (245, 95%CI 104  385) while the ST 
model does not (147, 95%CI -4  298). 
 
3.4. Sensitivity analysis 
Our sensitivity analyses results are presented in Table 5. For all cases, changing the temperature 
measure to minimum temperature results in a decrease in model fit. Improved model fits were 
observed for influenza and pneumonia related mortalities as well as influenza and cardiovascular 
related hospitalisations when we allowed the flu season to vary year on year. These improved 
models result in increases in the number of (a) influenza related deaths prevented (from 15 to 24), 
(b) pneumonia related deaths prevented (from 85 to 96), and (c) cardiovascular related 
hospitalisations prevented (from 52 to 56). It is worth noting that the changes in model fits did not 
alter the statistical significance of any reductions in mortality/hospitalisations. These sensitivity 
analyses did not produce any substantial changes to the impact of the vaccination campaign. 
 
Cause 
Baseline Min temp
*
Flu seasons
**
 
GCV score Reduction

GCV score Reduction

GCV score Reduction

 
Deaths 
All-cause 2.397 775 2.666 811 2.589 782 
Influenza 0.660 15 0.661 17 0.658 20 
Pneumonia 1.596 85 1.622 99 1.574 96 
Cardiovascular 2.196 310 2.235 351 2.198 324 
COPD 1.456 123 1.477 111 1.462 114 
 
Hospitalisations 
Influenza 0.698 24 0.700 19 0.686 13 
Pneumonia 1.415 147 1.426 105 1.421 74 
Cardiovascular 1.054 52 1.057 24 1.052 56 
COPD 1.778 236 1.796 175 1.784 125 
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*
Model uses the minimum temperature for the geographical centre of Scotland to define seasonal variability. 
Predictions are also adjusted for severity of temperature. 
**
Model uses consultation rates (reports per 100,000 population) to define the start and end of each flu season. 

The mean number of events prevented each flu season since mid-2000. 
 
Table 5. Sensitivity analysis results showing the GCV scores and the mean number of deaths and hospitalisations prevented 
amongst those aged 65 and over. For each outcome of interest, smaller GCV scores mean better model fits. 
4. Conclusions and discussion 
For the last 17 years, the UK has employed a routine influenza vaccination programme with the 
aim of reducing the spread of seasonal influenza 
(41)
. The programme has been extended to allow for 
the introduction of new risk groups and, in mid-2000, moved from a purely risk based approach to a 
risk and age group targeted approach with all those aged 65+ years being included 
(42)
. The 2012 JCVI 
recommendations to include 2  17 year olds 
(12)
 is a major undertaking that will require a substantial 
increase in NHS resources. To date, there has been no assessment of the population effectiveness of 
the age targeted policy introduced in Scotland in 2000. Understanding how that policy extension has 
affected influenza related morbidity and mortality is key to understanding the effectiveness of the 
current extension. 
In this paper we have used routine influenza surveillance data collected in Scotland for the 
period 1981  2012 to develop Poisson regression models to evaluate the population effectiveness 
of Scotland's national seasonal influenza vaccination programme. 
Our results suggests that mortality/hospitalisations amongst those aged 65+ years was 
reduced following the mid-2000 change in policy. In particular, we found evidence of reductions in 
all-cause mortality (WIY: 732; ST: 755 deaths prevented), COPD (WIY: 167; ST: 310 deaths 
prevented) and cardiovascular (WIY: 248; ST: 123 deaths prevented) related mortality, and COPD 
related hospitalisations (WIY: 425, ST: 236 hospitalisations prevented). 
It is believed that this study is the only one to analyse the population impact of the influenza 
vaccine on several causes of mortality/hospitalisations. Since 2008, there have been a number of 
groups looking at the annual effectiveness of the seasonal influenza vaccine
(43, 44, 45, 46)
, using mainly 
a test negative case-control study design, and these are now used to inform the WHO strain 
selection meetings each year. That said, previous studies that have examined the impact on 
mortality of routinely vaccinating those aged 65+ years have produced contradictory results. Studies 
in the US and Italy found no evidence of a reduction in all-cause mortality amongst the over 65s 
(47, 
48)
, while a study in Holland did find evidence of a reduction 
(49)
. The failure to find evidence in the US 
and Italian studies may be due to a limited period with sufficiently high vaccine coverage 
(31)
. There 
are few studies in the UK that have focused on the vaccination programme amongst those aged 65+ 
years. In contrast to our results for Scotland, Mann et al. 
(31)
 found weak evidence of a reduction in 
influenza and pneumonia related mortality in England and Wales following the mid-2000 policy 
change. However, their approach uses a longer definition of the flu year (week 26 to week 25), 
therefore incorporating deaths that occur outside the flu season. Furthermore, any estimates of 
negative excess deaths were recoded to 0. As a result, Mann et al. could potentially overestimate 
the impact of the change in vaccination policy. 
Data on consultation rates collected in Scotland shows that the start, end and duration of the flu 
season can vary from year to year. This suggests that our definition of a flu season, the fixed period 
from week 46 to week 9, may limit our ability to capture flu seasons that start early or finish late. 
Sensitivity analyses showed that allowing the flu season to vary from year to year did alter our 
estimates for the number of deaths/hospitalisations prevented each flu season. However, the 
changes in our estimates were, with the exception of pneumonia and COPD hospitalisations, 
relatively small. The changes in our estimates for pneumonia and COPD may be attributable to the 
following: while pneumonia and COPD admissions are at increased levels in the winter when flu is 
circulating, there are other infectious agents that can cause admissions for pneumonia and COPD 
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in the periods out with the winter. Furthermore, the model fits obtained from the varying flu 
season model were, for the most part, poorer than those obtained with the baseline model. 
We used two different methods to account for the seasonal variation in the data. This allowed us 
to validate our results and test the assumption that seasonal variation in mortality/hospitalisations is 
associated with temperature. For all-cause and cause specific mortality these two methods 
produced similar estimates of the vaccination campaign's impact. For cause specific hospitalisations, 
the two methods produced similar estimates of the vaccination campaign's impact for all but one of 
the hospitalisation categories: contradictory results for pneumonia related hospitalisations. Here the 
WIY model found evidence of a significant reduction while the ST model did not. This apparent 
contradiction may be attributable to the poorer model fits that were obtained using the ST model 
(data not shown). The poorer fits suggest that the variability in mortality/hospitalisations cannot be 
explained by temperature alone. This suggests that the WIY model, which uses a generic term to 
capture the seasonal variation, may be the most appropriate method to use. 
We have assumed throughout that any changes in the excess deaths/hospitalisations post 2000 
compared to pre-2000 are associated with the UKs influenza vaccination programme. It is possible 
that the changes may be associated with features like severity of flu, the use of antibiotics or disease 
modification drugs such as statins. We use a dummy binary variable to introduce the routine 
vaccination of all those aged 65+ in mid-2000. We assume no vaccine effect/availability prior to mid-
2000. Before mid-2000 the UK employed a risk-based vaccination strategy and it is likely that some 
of those aged 65+ would have been vaccinated as part of that programme. Therefore, there may be 
some vaccine effect pre-mid-2000 that our model does not account for which may lead to an over-
estimation of the effectiveness of the age-based vaccination policy. Unfortunately, yearly vaccine 
uptake data for Scotland is only available from 2001, after the introduction of the age-based 
vaccination strategy, and we are therefore unable to adjust for vaccine uptake or use vaccine uptake 
as a predictor variable.  There has been an increase in vaccine uptake amongst those aged 65+ years 
over the period 2001  2012 but there is no evidence from Figure 2 of a trend to have increased 
reductions in the excess post 2001 and this suggests that vaccine uptake is not an explanation.  
Similarly, antibiotic use has increased steadily over the post 2001 period and the lack of a trend 
suggests this is not a contributing factor. Furthermore, the trends in our data may be associated with 
behavioural changes like reduced rates of smoking (smoking may predispose the individual to 
increased complication from influenza or other respiratory infections more evident in the winter). 
The inability to account for these other features in our model may lead to an overestimation of the 
amount of morbidity and mortality that has been prevented by the UKs influenza vaccination 
programme. 
Previous analyses of excess winter deaths have use Serfling type models based upon sine and 
cosine terms to model the cyclical pattern to mortality within a year 
(31, 50, 51)
. With such models, 
where the data used to fit the model come from the summer months only, the excess deaths in 
winter are the difference between the observed and the deaths predicted assuming that the spring 
summer autumn seasonal trend carries on into winter.  Such models are not appropriate for our 
work as (1) there is always likely to be an excess each season and (2) they do not properly fit the 
winter peak.  To achieve the latter, it is more appropriate to use either more harmonic terms in a 
Serfling type model or to use GAMS which have greater flexibility to fit to the winter peak.  We use 
GAMS because we assess the impact of the vaccination campaign by fitting the model to all the pre-
vaccination data, both summer and winter, so that we have a model which, when projected into the 
future gives predictions of the number of deaths in winter, assuming that there had not been an 
intervention - the age-related vaccination campaign.  We also fit to the summer data in the 
intervention period so that we can fit to general trends of decreasing mortality in the intervention 
period.  Failure to do so would mean extrapolating the general decreasing trends from 1981  1999 
10  13 years into the future.  This is not optimal as the trends are unlikely to continue up to 10  13 
years into the future. 
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In conclusion, our work suggests that influenza related morbidity and mortality amongst those 
aged 65+ years has reduced following the decision to extend the UK's vaccination policy to 
incorporate all persons aged 65 and over. Given the recent recommendations to extend the 
programme to all those aged 2  17, these results provide healthcare professionals and policy 
makers with an important benchmark from which to assess the success of the most recent 
recommendation. Furthermore, the methods used in this analysis provide a framework that can be 
used to analyse the population effectiveness of the new influenza vaccination programme once the 
2  17-year-old extension has been implemented. 
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